AI search is redrawing the beauty discovery map, and ingredient-led brands are the only ones with a passport
When LLMs surface beauty recommendations, they prioritise clinical credibility over brand narrative. The Ordinary, CeraVe, and La Roche-Posay are dominating AI citations not because they spent more on media but because their entire brand architecture is built around searchable, citable, expert-legible claims. This is a structural advantage that most mid-market beauty brands cannot retrofit quickly. The brands that spent the last decade building emotional storytelling are now invisible to the fastest-growing discovery channel.
Daniel Ek's full-body scan startup raised $700M at a valuation that confirms preventive health is now a luxury consumption category, not a medical one.
Percival's shoot at Leyton Orient is not a sports crossover, it is a statement that football heritage carries more cultural weight than traditional menswear references right now.
Calling overproduction the focus, not sustainability in the abstract, is a specific commercial argument. It reframes restraint as strategy, not sacrifice.
A museum that curated temporary exhibitions for over a century committing to a permanent collection display is an institutional signal that design is ready to be canonised, not just celebrated.
Surface Magazine
The Pattern · today's connecting thread
Credibility replaced story. Brands built on feeling are invisible now.
Three signals today point to the same structural shift: the brands winning in AI-mediated discovery (The Ordinary, CeraVe), the brands winning in health investment (Neko Health with its clinical scanning model), and the brand winning in sustainable retail (TOAST with its production-first argument) all lead with verifiable claims, not emotional narratives.
The common thread is legibility: in an environment where algorithms, not editors, make the first recommendation, a brand that cannot be cited cannot be found. The decade-long investment in brand story is not worthless, but it is no longer sufficient as the primary architecture.
Mike LitmanCurator · The Pattern
The Dissent
The breathless framing around AI citation dominance for ingredient brands misses a structural ceiling: LLMs are trained on historical data, and the brands dominating citations today, CeraVe, La Roche-Posay, The Ordinary, built their ingredient credibility over ten to fifteen years of consistent SEO, editorial coverage, and dermatologist endorsement. Newer brands cannot manufacture that citation depth in a single repositioning cycle, but neither can they afford to ignore the channel. The real strategic risk is not that emotional brands lose AI search today; it is that they invest in clinical retrofitting that arrives too late, after the citation models have already consolidated around the incumbents.
We Predict
Unilever will announce a formal AI-citation optimisation strategy for its skincare portfolio, naming specific brands, before the end of Q3 2026.
Confidence: 60%
Within By end of Q3 2026
Today's Glossy report confirms that AI citation dominance in beauty is already a measurable competitive advantage, with ingredient-led brands outperforming emotional narrative brands in LLM recommendations. Unilever owns brands on both sides of this divide, including Dove and Simple, and its marketing leadership has been publicly vocal about AI-driven discovery since late 2025. The mechanism is straightforward: a major FMCG group with a skincare portfolio this size cannot ignore a new discovery channel where its competitors are structurally advantaged. The alternative hypothesis is that Unilever moves quietly through agency briefings rather than a public announcement, which would make this call unresolvable and is the primary risk to it landing.
One to Watch
Neko Health: preventive care as the new luxury category
A $700 million raise at a $7 billion valuation positions Neko Health as the defining benchmark for what premium health consumption looks like in 2026. Its model is clinical and data-driven, not aspirational, and that is precisely why it is attracting capital at this scale. Watch how traditional luxury wellness brands respond: the ones that move towards verifiable health outcomes will hold relevance, and the ones that stay in the language of feeling will cede the high end of the market.
Conversation Starters
If AI citation is now the primary beauty discovery channel, does your brand have enough clinical architecture to appear at all?
Neko Health is valued at $7 billion on prevention data alone. At what point does your wellness brand need a clinical credibility layer, not just a wellness aesthetic?
TOAST calls overproduction the focus, not sustainability. Is your brand's restraint a production model or still just a messaging position?
For people who’d rather be early and wrong than late and safe.